Covered recipient · General Payments record
LAWRENCE I KARSH
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$131,398.42
179 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,047.97 | 35 |
| Consulting Fee | $32,866.00 | 9 |
| Travel and Lodging | $12,148.64 | 57 |
| Food and Beverage | $3,307.35 | 74 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000.00 | 1 |
| Education | $28.46 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $45,469.53 | 45 |
| Bayer HealthCare Pharmaceuticals Inc. | $27,113.68 | 42 |
| Astellas Pharma US Inc | $17,334.74 | 28 |
| PFIZER INC. | $10,968.46 | 18 |
| Ferring Pharmaceuticals Inc. | $8,321.01 | 11 |
| Astellas Pharma Global Development | $7,988.22 | 6 |
| AstraZeneca Pharmaceuticals LP | $5,761.04 | 6 |
| Foundation Medicine, Inc. | $3,948.96 | 6 |
| Clovis Oncology, Inc. | $2,695.29 | 5 |
| Dendreon Pharmaceuticals LLC | $1,472.68 | 2 |
| Genentech, Inc. | $101.86 | 1 |
| COMSORT, Inc | $100.00 | 1 |
| Endo Pharmaceuticals Inc. | $52.22 | 3 |
| Blue Earth Diagnostics Limited | $19.78 | 1 |
| Amgen Inc. | $17.45 | 1 |
| Allergan Inc. | $13.26 | 1 |
| AbbVie, Inc. | $11.70 | 1 |
| Janssen Pharmaceuticals, Inc | $8.54 | 1 |
Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAWRENCE I KARSH
NPI 1194766279 · CMS profile ID 280656
Allopathic & Osteopathic Physicians / Urology
DENVER, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAWRENCE I KARSH, NPI 1194766279, CMS profile ID 280656. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). LAWRENCE I KARSH, NPI 1194766279, CMS profile ID 280656. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- LAWRENCE I KARSH, NPI 1194766279, CMS profile ID 280656, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 179 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194766279?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
179 matching records · $131,398.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 179.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $2.32 | 10/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516085 | CMS |
| Janssen Biotech, Inc. | $14.99 | 10/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516073 | CMS |
| PFIZER INC. | $330.00 | 10/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673846831 | CMS |
| PFIZER INC. | $4,845.00 | 10/21/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673020835 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 10/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685132141 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,611.00 | 10/17/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685450991 | CMS |
| Astellas Pharma US Inc | $22.17 | 10/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629027 | CMS |
| Janssen Biotech, Inc. | $69.60 | 10/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516069 | CMS |
| Janssen Biotech, Inc. | $1.72 | 10/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516065 | CMS |
| Janssen Biotech, Inc. | $12.31 | 10/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516063 | CMS |
| Astellas Pharma US Inc | $16.22 | 10/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629023 | CMS |
| Janssen Biotech, Inc. | $4,100.00 | 10/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516059 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $5,200.00 | 10/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628466775 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $3,120.00 | 10/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628467091 | CMS |
| AstraZeneca Pharmaceuticals LP | $69.60 | 09/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685261821 | CMS |
| AstraZeneca Pharmaceuticals LP | $78.39 | 09/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685636871 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $22.71 | 09/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628426359 | CMS |
| AstraZeneca Pharmaceuticals LP | $52.05 | 09/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685508801 | CMS |
| Janssen Biotech, Inc. | $217.81 | 09/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516055 | CMS |
| Janssen Biotech, Inc. | $59.97 | 09/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516051 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,250.00 | 09/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685830875 | CMS |
| Astellas Pharma US Inc | $3,325.00 | 09/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629017 | CMS |
| Astellas Pharma US Inc | $28.60 | 09/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629019 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $69.35 | 09/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628483345 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $74.43 | 09/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628472001 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $74.43 | 09/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628492557 | CMS |
| Endo Pharmaceuticals Inc. | $15.25 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685076673 | CMS |
| Astellas Pharma US Inc | $17.33 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629013 | CMS |
| PFIZER INC. | $11.50 | 09/05/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673293671 | CMS |
| Janssen Biotech, Inc. | $4,040.00 | 08/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516047 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,550.00 | 08/26/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628490203 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $108.65 | 08/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628425703 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $21.65 | 08/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628471079 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $13.00 | 08/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628480131 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $30.00 | 08/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628492443 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,550.00 | 08/19/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628480903 | CMS |
| Janssen Biotech, Inc. | $33.16 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516035 | CMS |
| Janssen Biotech, Inc. | $28.42 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516039 | CMS |
| Janssen Biotech, Inc. | $47.37 | 08/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516043 | CMS |
| Janssen Biotech, Inc. | $731.89 | 08/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516031 | CMS |
| Dendreon Pharmaceuticals LLC | $29.71 | 08/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703763593 | CMS |
| Janssen Pharmaceuticals, Inc | $8.54 | 08/14/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658814243 | CMS |
| Astellas Pharma US Inc | $8.42 | 08/01/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629007 | CMS |
| Astellas Pharma US Inc | $15.41 | 08/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629009 | CMS |
| COMSORT, Inc | $100.00 | 08/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804673 | CMS |
| Endo Pharmaceuticals Inc. | $18.97 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685076669 | CMS |
| Janssen Biotech, Inc. | $500.00 | 07/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658516028 | CMS |
| Amgen Inc. | $17.45 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662629763 | CMS |
| Astellas Pharma US Inc | $124.81 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655629003 | CMS |
| PFIZER INC. | $15.52 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672309785 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,210.00 | 3 |
| PY2025 | Principal investigator | $1,397,669.97 | 141 |
| PY2024 | Recipient | $8,120.00 | 9 |
| PY2024 | Principal investigator | $955,667.13 | 105 |
| PY2023 | Recipient | $5,875.67 | 11 |
| PY2023 | Principal investigator | $783,568.93 | 158 |
| PY2022 | Recipient | $3,499.06 | 2 |
| PY2022 | Principal investigator | $1,384,612.39 | 192 |
| PY2021 | Recipient | $5,066.33 | 4 |
| PY2021 | Principal investigator | $1,601,811.00 | 172 |
| PY2020 | Recipient | $4,732.50 | 7 |
| PY2020 | Principal investigator | $1,691,275.92 | 248 |
| PY2019 | Principal investigator | $1,133,326.18 | 201 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
144 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/30/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726486 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 12/24/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740712 |
| Principal investigator 1 | Janssen Research & Development, LLC | $381.00 | 12/18/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175416199 |
| Principal investigator 1 | Janssen Research & Development, LLC | $311.00 | 12/18/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416267 |
| Principal investigator 1 | Janssen Research & Development, LLC | $224.00 | 12/18/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175416296 |
| Principal investigator 1 | Janssen Research & Development, LLC | $509.04 | 12/12/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $910.00 | 11/24/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416217 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $877.50 | 11/12/2025 | Non-covered Recipient Entity The Urology Center Of Colorado | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419731 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,225.50 | 11/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654686 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $450.00 | 11/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654792 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.00 | 11/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654891 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,941.00 | 11/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654946 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.00 | 11/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176655060 |
| Principal investigator 1 | MEDIVATION LLC. | $1,312.20 | 11/04/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739566 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 11/04/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228748014 |
| Principal investigator 1 | PFIZER INC. | $26,929.00 | 11/04/2025 | Non-covered Recipient Entity Adventist Health SystemSunbelt Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228739334 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/03/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727161 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 10/31/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723842 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,339.00 | 10/27/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416272 |
| Principal investigator 1 | Janssen Research & Development, LLC | $976.00 | 10/13/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175416206 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 10/13/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726622 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 10/11/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725822 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $438.75 | 10/10/2025 | Non-covered Recipient Entity The Urology Center Of Colorado | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419701 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 10/01/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739372 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 10/01/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228746561 |
| Principal investigator 1 | Janssen Research & Development, LLC | $580.00 | 09/19/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416300 |
| Principal investigator 1 | Janssen Research & Development, LLC | $336.00 | 09/08/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175416278 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 09/01/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743263 |
| Principal investigator 1 | Janssen Research & Development, LLC | $641.00 | 08/25/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416289 |
| Principal investigator 1 | Janssen Research & Development, LLC | $869.00 | 08/18/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175416254 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 08/15/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228742936 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 08/15/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743072 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 08/15/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743316 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 08/13/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727397 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 08/12/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726620 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 08/01/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641706 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,225.50 | 08/01/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641741 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.00 | 08/01/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,429.00 | 07/24/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416239 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,225.50 | 07/09/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640397 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,118.00 | 06/30/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,370.10 | 06/18/2025 | Non-covered Recipient Entity The Uro Ctr Of Colorado Computed Tomography | A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175183812 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 06/16/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175416315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 06/13/2025 | Non-covered Recipient Entity The Uro Ctr Of Colorado | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175183641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,490.00 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416223 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723960 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228781326 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790146 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790510 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791464 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791595 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792433 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793114 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 06/02/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793320 |
| Principal investigator 1 | Janssen Research & Development, LLC | $381.00 | 05/29/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175416282 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 05/14/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753471 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 05/13/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753829 |
| Principal investigator 1 | PFIZER INC. | $138,623.67 | 05/13/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754331 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.00 | 05/07/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634282 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $28,363.50 | 05/07/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634301 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719759 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789909 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790130 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790303 |
| Principal investigator 1 | MEDIVATION LLC. | $1,312.20 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790366 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790595 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791146 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791344 |
| Principal investigator 1 | MEDIVATION LLC. | $590.63 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791431 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791455 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791593 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791606 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791704 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792048 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792122 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792156 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792476 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792685 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792692 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792789 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793427 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793667 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793757 |
| Principal investigator 1 | MEDIVATION LLC. | $1,143.45 | 05/05/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793999 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,387.00 | 04/28/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416244 |
| Recipient | PFIZER INC. | $940.00 | 04/27/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770986 |
| Principal investigator 1 | BioXcel Therapeutics, Inc. | $613.54 | 04/04/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | BXCL-701-201 | No dispute reported | 06/30/2026 | 1228697961 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/02/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751909 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719793 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719971 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228720183 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723564 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228779595 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228780853 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228781185 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789846 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789955 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789974 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790065 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790269 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790296 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790701 |
| Principal investigator 1 | MEDIVATION LLC. | $590.63 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790787 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790892 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790907 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791028 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791257 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791331 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791373 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791490 |
| Principal investigator 1 | MEDIVATION LLC. | $18.60 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791656 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791785 |
| Principal investigator 1 | MEDIVATION LLC. | $251.10 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791926 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791966 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792051 |
| Principal investigator 1 | MEDIVATION LLC. | $18.60 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792415 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792584 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792629 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792633 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792757 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792845 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792914 |
| Principal investigator 1 | MEDIVATION LLC. | $72.30 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793329 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793499 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793640 |
| Principal investigator 1 | MEDIVATION LLC. | $43.75 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793657 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793764 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793769 |
| Principal investigator 1 | MEDIVATION LLC. | $18.60 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793778 |
| Principal investigator 1 | MEDIVATION LLC. | $84.70 | 04/01/2025 | Non-covered Recipient Entity THE UROLOGY CENTER OF COLORADO | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793996 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/01/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753128 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/01/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228758009 |
| Principal investigator 1 | Janssen Research & Development, LLC | $488.00 | 03/31/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175416191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $538.00 | 03/27/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416250 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 03/14/2025 | Non-covered Recipient Entity The Uro Ctr Of Colorado | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175183594 |
| Principal investigator 1 | Janssen Research & Development, LLC | $891.00 | 02/24/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,732.00 | 02/03/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175416212 |
| Principal investigator 1 | Janssen Research & Development, LLC | $112.00 | 02/03/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175416230 |
| Principal investigator 1 | Janssen Research & Development, LLC | $976.00 | 02/03/2025 | Non-covered Recipient Entity PORTERCARE ADVENTIST HEALTH SYSTEM | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175416261 |
| Recipient | PFIZER INC. | $940.00 | 02/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751995 |
| Recipient | PFIZER INC. | $330.00 | 01/15/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769929 |
| Principal investigator 1 | PFIZER INC. | $138,623.67 | 01/09/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722722 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 01/09/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753459 |
| Principal investigator 1 | PFIZER INC. | $138,618.36 | 01/09/2025 | Non-covered Recipient Entity Advent Health Medical Group Urology Denver | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753467 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $0.01 | 1 |
| PY2025 | Value of interest | $0.01 | 1 |
| PY2024 | Amount invested | $0.01 | 1 |
| PY2024 | Value of interest | $0.01 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $0.01 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
3 records · PY2023–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | SWAN VALLEY MEDICAL INCORPORATED | $0.01 | $0.01 | These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2025, the shares the doctors own are without value. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1205963608 |
| PY2024 | SWAN VALLEY MEDICAL INCORPORATED | $0.01 | $0.01 | These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2024, the shares the doctors own are without value. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1126752480 |
| PY2023 | SWAN VALLEY MEDICAL INCORPORATED | $0.00 | $0.01 | Shares listed were purchased or granted for services in past reported years. The current value of these shares is the par value of $0.01. The Company is a privately held C Corporation with no public market for the sale of its highly restricted stock. The Company is has never been profitable and its liabilities currently exceed its assets, with operating expenses exceeding its sales revenues. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 984043599 |